Handelsavisen
prelaunch
Companies Healthcare ALEC.DU
AL
ALEC.DU Pharmaceuticals & Medical Research

ALEC Holdings PJSC

$1,38
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
3,40 %
Op margin
6,8 %
ROE
47,1 %
Net margin
5,4 %
Debt / equity
0,67
Beta
52w range
Volume
Day range
Prev close
$2,19
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

ALEC Holdings PJSC operates in the Construction & Engineering industry within the Industrials sector, generating revenue through engineering and construction activities.

Business. ALEC Holdings PJSC operates in the Construction & Engineering industry within the Industrials sector, generating revenue through engineering and construction activities.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target1,90

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
1,90
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability
47,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ALEC.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ALEC.DU. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ALEC Holdings PJSC operates in the Construction & Engineering industry within the Industrials sector, generating revenue through engineering and construction activities.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    ALEC Holdings PJSC maintains a leveraged capital structure with total liabilities of 9.23 billion AED against total equity of 1.39 billion AED, resulting in a debt-to-equity ratio of 0.67. The company holds long-term debt of 937.2 million AED and reports a current ratio of 1.28, indicating adequate short-term liquidity coverage. Operating cash flow stands at 1.36 billion AED, while free cash flow is 560.6 million AED after capital expenditures of 392.7 million AED. The risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, highlighting reliance on external financing or cash flow generation to service obligations.

    Profitability metrics show a return on equity of 47.1% and a return on assets of 6.18%, reflecting efficient use of equity despite the high leverage. The company generated a gross profit of 1.32 billion AED and an operating income of 836.6 million AED on revenues of 12.6 billion AED, yielding a net income of 686.2 million AED. Without cohort median data for direct comparison, these returns appear robust relative to the asset base, though the high debt load necessitates careful monitoring of interest coverage and refinancing risks.

    Segment and geographic revenue breakdowns are not provided in the available data, preventing analysis of revenue concentration or regional exposure. The absence of segment data limits the ability to assess diversification benefits or specific market risks within the construction and engineering portfolio.

    Historical revenue and net income trends are not available in the input data, so growth trajectory analysis cannot be performed. The lack of multi-period data prevents evaluation of revenue stability, margin trends, or earnings consistency over time.

    Risk factors include medium liquidity risk and low dilution risk, with a key flag indicating negative net cash after debt subtraction. The company has 5 billion shares outstanding with no difference between basic and diluted shares, suggesting minimal immediate dilution pressure from options or convertible securities. The low dilution risk assessment supports the stability of current shareholder equity, though the negative net cash position remains a primary concern.

    Recent analyst observations indicate a mean price target of 1.90 AED with a mean recommendation of 2.00, reflecting a buy consensus. Two analysts issued buy ratings, with no strong buy, hold, or sell ratings recorded, suggesting moderate confidence in the company's near-term prospects. The uniform price target across high, low, and median estimates indicates limited dispersion in analyst expectations.

    Key takeaways
    • High return on equity of 47.1% driven by significant leverage and efficient asset utilization.
    • Negative net cash position after debt subtraction poses medium liquidity risk despite positive operating cash flow.
    • Analyst consensus is a buy with a uniform price target of 1.90 AED, indicating moderate confidence.
    • Low dilution risk with no difference between basic and diluted shares outstanding.
    • Lack of segment and historical data limits comprehensive growth and diversification analysis.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Analysts project 37.7% upside to a consensus price target of 1.90, reflecting strong market confidence.

    Net margin of 5.42% exceeds the cohort median of 5.28%, demonstrating better profitability than peers.

    Cash conversion of 2.07 is well above the cohort median of 1.20, highlighting strong cash generation.

    Low leverage band with a debt-to-equity ratio of 0.30 suggests a conservative and stable capital structure.

    BEAR CASE · 2

    Medium liquidity risk flag suggests potential challenges in meeting short-term obligations compared to safer peers.

    Debt-to-equity ratio of 0.67 is below the cohort median of 0.40, implying higher leverage than average.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-08
    Q1 2026 · Quarter highlights
    Open report →

    Revenue AED 4.61B, +86,8% YoY; Operating income +95,7% YoY.

    RevenueAED 4.61B+86,8 % YoY
    Operating incomeAED 288.3M+95,7 % YoY
    Net incomeAED 230.6M+100,8 % YoY
    Free cash flowAED 203.6M+80,3 % YoY
    EPS
    Operating cash flow-AED 398.7M+7,5 % YoY
    Financials
    Income statement
    RevenueAED 4.61B
    Gross profitAED 409.8M
    Operating incomeAED 288.3M
    Net incomeAED 230.6M
    Margins
    Gross margin8.9%
    Operating margin6.3%
    Net margin5.0%
    FCF margin4.4%
    Balance sheet
    Total assetsAED 11.49B
    Total liabilitiesAED 10.12B
    Total equityAED 1.37B
    Cash & equivalents
    Long-term debtAED 889.5M
    Cash flow
    Operating cash flow-AED 398.7M
    CapEx-AED 100.1M
    Free cash flowAED 203.6M
    SBC
    P&L flow · revenue → net income
    Revenue AED 4.61BOperating costs AED 4.32BTax AED 57.6MNet income AED 230.6M
    Highlights
    • Revenue AED 4.61B, +86,8% YoY
    • Operating income +95,7% YoY
    • Net income +100,8% YoY
    • Free cash flow +80,3% YoY
    • Net margin 5.0%

    Valuation FY

    Market price
    $1,38
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.39B
    Net cash
    -$937.2M
    Current ratio
    1.3
    Debt / equity
    0.7
    ROA
    6.2%
    ROE
    47.1%
    Cash conversion
    207.0%
    CapEx / revenue
    -3.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    EPC & Engineering Services
    low · llm_fanout_v2
    Industrial Plant Construction
    low · llm_fanout_v2

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)ALEC 0,1% · rank #45 of 109

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs ALEC · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    +506,8 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    +418,5 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    +306,2 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    +471,4 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    +485,3 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    +408,8 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,21
    Predicted surprise
    -0,08
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-11 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,21
    Revenueno estimateno estimate18,1B AED
    Operating incomeno estimateno estimate1,3B AED
    Full-year consensus mean (period as reported by source) · consensus in AED. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$1,90 · Median $1,90
    Low $1,90High $1,90
    Operating income · consensus1,3B AED
    EPS surprise
    −36,3 %
    reported vs consensus · miss
    Revenue surprise
    −30,2 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$1,90
    Mean$1,90
    Median$1,90
    High$1,90
    Spot$1,38
    +37.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin6,8 %Above P75
    Net Margin5,4 %Above P75
    ROE47,1 %Above P75
    Capex / Rev-3,2 %Below median
    D/E0,67Bottom quartile
    Cash Conv2,07Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 66 150 sh7 grants7 insiders
    • LAVIGNE LOUIS J JRDirector · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
    • Altmeyer MarkDirector · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
    • GAROFALO ELIZABETH A.Director · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
    • Hammond PaulaDirector · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
    • SCHELLER RICHARD HDirector · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
    • Yaffe KristineDirector · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
    • DESOUZA ERROL BDirector · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Assets
      net_income / total_assets
    • Return On Equity
      net_income / total_equity
    Source documents
    • ALEC Holdings PJSC Market data — financials · 2026-07-11
    • ALEC Holdings PJSC Market data — analyst estimates · 2026-07-11

    Ownership & reference

    Top holders

    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$41M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$5M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$4M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$11M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$4M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling0 buys · 16 sellsnet -$727K11 insiders · last 365d
    • Yaffe KristineDirector · Common StockOther 28 700 · 2026-06-17
    • LAVIGNE LOUIS J JRDirector · Common StockOther 28 700 · 2026-06-17
    • DESOUZA ERROL BDirector · Common StockOther 28 700 · 2026-06-17
    • Altmeyer MarkDirector · Common StockOther 28 700 · 2026-06-17
    • GAROFALO ELIZABETH A.Director · Common StockOther 28 700 · 2026-06-17
    • Hammond PaulaDirector · Common StockOther 28 700 · 2026-06-17
    • SCHELLER RICHARD HDirector · Common StockOther 28 700 · 2026-06-17
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 3 475 @ $1,88$7K · 2026-06-03
    • Rosenthal ArnonDirector, Chief Executive Officer · Common StockSold 87 216 @ $1,97$172K · 2026-06-02
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 5 709 @ $1,97$11K · 2026-06-02
    • Berkley Neil LindsayCFO & Chief Business Officer · Common StockSold 19 360 @ $1,97$38K · 2026-06-02
    • SCHELLER RICHARD HDirector · Common StockOther 10 833 · 2026-06-01
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 1 820 @ $2,65$5K · 2026-04-16
    • Berkley Neil LindsayCFO & Chief Business Officer · Common StockOther 54 600 · 2026-03-15
    • Rosenthal ArnonDirector, Chief Executive Officer · Common StockOther 116 246 · 2026-03-13
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 1 000 @ $2,65$3K · 2026-03-10
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 3 367 @ $2,08$7K · 2026-03-03
    • Rosenthal ArnonDirector, Chief Executive Officer · Common StockSold 81 864 @ $2,12$174K · 2026-03-02
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 8 071 @ $2,12$17K · 2026-03-02
    • Berkley Neil LindsayCFO & Chief Business Officer · Common StockSold 29 649 @ $2,12$63K · 2026-03-02
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 4 079 @ $2,50$10K · 2026-02-26
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 4 753 @ $1,21$6K · 2025-12-05
    • Rosenthal ArnonDirector, Chief Executive Officer · Common StockSold 104 347 @ $1,12$117K · 2025-12-03
    • Wong-Sarad GracePrincipal Accounting Officer · Common StockSold 8 056 @ $1,12$9K · 2025-12-03
    • Berkley Neil LindsayChief Bus Ofcr & Interim CFO · Common StockSold 37 261 @ $1,12$42K · 2025-12-03

    Short positioning

    5.7Mshares short-0.9% vs prior
    10.19days to cover
    54.2%short of daily vol
    2.7Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ALEC.DUCanonical
    — · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,08Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -37.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -7.6%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -79.1%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -33.8%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -96.7%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -23.1%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 99.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -13.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -75.8%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -13.0%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -20.2%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 20.0%Derived (calculated)
    • Current ratio (FY 2025-12-31): 3.83xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 8.57xDerived (calculated)
    • Return on equity (FY 2025-12-31): -466.6%Derived (calculated)
    • Return on assets (FY 2025-12-31): -48.8%Derived (calculated)
    • Net margin (FY 2025-12-31): -679.5%Derived (calculated)
    • Total assets (annual): USD 293.24MSEC XBRL filing
    • Total liabilities (annual): USD 262.59MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
    • R&D expense (annual): USD 123.06MSEC XBRL filing
    • Pre-tax income (annual): USD -142.76MSEC XBRL filing
    • Cash & equivalents (annual): USD 65.8MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-17 00:00 UTCINSIDER19 insider transactions — 2026-06 · net sell $228k 7 derivative
    2026-06-17FILING8-K filing →
    2026-06-17INSIDERYaffe Kristine transacted 28.7k sh — Director
    2026-06-17INSIDERLAVIGNE LOUIS J JR transacted 28.7k sh — Director
    2026-06-17INSIDERDESOUZA ERROL B transacted 28.7k sh — Director
    2026-06-17INSIDERAltmeyer Mark transacted 28.7k sh — Director
    2026-06-17INSIDERGAROFALO ELIZABETH A. transacted 28.7k sh — Director
    2026-06-17INSIDERHammond Paula transacted 28.7k sh — Director
    2026-06-17INSIDERSCHELLER RICHARD H transacted 28.7k sh — Director
    2026-06-17INSIDERDESOUZA ERROL B acquired 9.4k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERSCHELLER RICHARD H acquired 9.4k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERYaffe Kristine acquired 9.4k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERGAROFALO ELIZABETH A. acquired 9.4k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERHammond Paula acquired 9.4k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERLAVIGNE LOUIS J JR acquired 9.4k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERAltmeyer Mark acquired 9.4k sh Stock Option (right to buy) — Director
    2026-06-03INSIDERWong-Sarad Grace sold 3.5k sh — Principal Accounting Officer ~$7k
    2026-06-02INSIDERRosenthal Arnon sold 87.2k sh — Director, Chief Executive Officer ~$172k
    2026-06-02INSIDERWong-Sarad Grace sold 5.7k sh — Principal Accounting Officer ~$11k
    2026-06-02INSIDERBerkley Neil Lindsay sold 19.4k sh — CFO & Chief Business Officer ~$38k
    2026-06-01INSIDERSCHELLER RICHARD H transacted 10.8k sh — Director
    2026-05-08 20:07 UTCEARNINGSQuarterly results — Q1 2026 Revenue AED 4.61B · Net AED 230.6M
    2026-05-07FILING8-K filing →
    2026-05-07FILING424B5 filing →
    2026-05-07FILING10-Q filing →
    2026-05-07FILING8-K filing →
    2026-04-28FILINGDEF 14A filing →
    2026-04-16 00:00 UTCINSIDER1 insider transaction — 2026-04
    2026-04-16INSIDERWong-Sarad Grace sold 1.8k sh — Principal Accounting Officer ~$5k
    2026-03-15 00:00 UTCINSIDER7 insider transactions — 2026-03 · net sell $264k
    2026-03-15INSIDERBerkley Neil Lindsay transacted 54.6k sh — CFO & Chief Business Officer
    2026-03-13INSIDERRosenthal Arnon transacted 116.2k sh — Director, Chief Executive Officer
    2026-03-10INSIDERWong-Sarad Grace sold 1.0k sh — Principal Accounting Officer ~$3k
    2026-03-03INSIDERWong-Sarad Grace sold 3.4k sh — Principal Accounting Officer ~$7k
    2026-03-02INSIDERRosenthal Arnon sold 81.9k sh — Director, Chief Executive Officer ~$174k
    2026-03-02INSIDERWong-Sarad Grace sold 8.1k sh — Principal Accounting Officer ~$17k
    Showing the 40 most recent of 56 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage